Colorectal Cancer Alliance Applauds President Biden’s Choice for NIH Director
Statement from Michael Sapienza, CEO of the Colorectal Cancer Alliance, on the nomination of Dr. Monica Bertagnolli for Director of the National Institutes of Health:
"The Colorectal Cancer Alliance supports President Biden's nomination of Dr. Monica Bertagnolli for Director of the National Institutes of Health (NIH). Dr. Bertagnolli's transformative work as the Director of the National Cancer Institute (NCI) and her unwavering commitment to advancing cancer research align with the Colorectal Cancer Alliance's mission to end colorectal cancer in our lifetime.
Dr. Bertagnolli has demonstrated a firm commitment to the vision of President Biden's Cancer Moonshot, an initiative we support for its immense life-saving potential. Her innovative efforts in cancer prevention, early detection, and creating a national navigation program for childhood cancers are significant strides toward eradicating this disease. Her dedication is demonstrated further by initiatives to enhance data infrastructure and clinical research to benefit patients.
We applaud her many achievements, including her historic role as the first woman to serve as the Director of the NCI, and her influential positions at institutions such as Harvard Medical School, Brigham and Women's Hospital, and Dana-Farber Cancer Institute. Her impact extends even further, as seen in her service on the boards of the American Society of Clinical Oncology, the American Cancer Society, and the Prevent Cancer Foundation.
Dr. Bertagnolli's nomination is a testament to her vision, leadership, and devotion to advancing health research and care. We are confident the patients and caregivers served by the Colorectal Cancer Alliance would benefit from her service in this role, and we stand behind this well-deserved nomination."
Top resources
Alliance Honors Survivors, Encourages Screening and Advocates for Research During National Cancer Survivors Month
In recognition of National Cancer Survivors Month this June, the Colorectal Cancer Alliance (Alliance) is shining a light on the more than 1.5 million colorectal cancer survivors in the United States, celebrating their strength while calling attention to increasing rates of colorectal cancer and the urgent need for more screening and research to end the disease.
Hope in the Details: How Heather’s Biomarker Opened New Treatment Paths
After a stage IV colorectal cancer diagnosis, Heather’s biomarker test revealed a critical mutation — opening the door to clinical trials and new hope.
Alliance Announces New Leadership Roles
The additions to the Colorectal Cancer Alliance's all bring deep expertise and a shared passion for the mission to end colorectal cancer in our lifetime.